Skip to main content
SpringerLink
Log in

High-Dose Chemotherapy in Breast Cancer

  • Chapter
High-Risk Breast Cancer

  • 96 Accesses

Abstract

In 1891 Brown-Sequard attempted to augment human bone marrow orally [1]. Over the next five decades allogeneic marrow was administered intramuscularly [2] and by intramedullary injection [3], before the intravenous route was found to be optimal in 1939 [4]. Between 1945 and 1965 the effects of total body radiotherapy were studied and the immunocompatibility complex was identified. The first series of patients transplanted for relapsed leukemia and aplastic anemia was published in 1968 [5]. In 1977, Thomas and colleagues in Seattle reported that 13 of 100 patients with relapsed acute leukemia at the time of transplant were disease free 1–4.5 years later [6]. Today more than half of acute myelogenous leukemia patients transplanted during first remission with HLA-matched sibling donor marrow are now cured [7–8]. Substantial gains made in the prevention of graft-versus-host disease and in supportive care (platelet transfusions and a wider variety of effective antibiotics) have considerably decreased the risks of high dose therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Quine WE (1986) The remedial application of bone marrow. JAMA 26: 1012–1013

    Google Scholar 

  2. Schretzenmayr A (1937) Anamiebehandlung mit Knochenmarksinjektionen. Klin Wochenschr 16: 1010–1012

    Article  Google Scholar 

  3. Migdalska KZ (1958) Special section - transplantation of bone marrow. Blood 13: 300–301

    Google Scholar 

  4. Osgood EE, Riddle MC, Mathews TJ (1939) Aplastic anaemia treated with daily transfusions and intravenous marrow. Ann Interm Med 13: 357–367

    Google Scholar 

  5. Mathe G (1968) Bone marrow transplantation. In: Rappaport FT, Dausset J (eds) Human transplantation. Grune and Stratton, New York, pp 284–303

    Google Scholar 

  6. Thomas ED, Buckner CD, Banaji M et al. (1977) One hundred patients with acute leukemia treated by chemotherapy, total body irradiation and allogeneic marrow transplantation. Blood 49: 511–5337.

    PubMed  CAS  Google Scholar 

  7. Thomas ED (1982) The role of marrow transplantation in the eradication of malignant disease. Cancer 49: 1963–1969

    Article  PubMed  CAS  Google Scholar 

  8. Appelbaum FR, Dahlberg S, Thomas ED et al. (1984) Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. Ann Intern Med 101: 581–588

    PubMed  CAS  Google Scholar 

  9. Kurnick NB, Feder BH, Montano A et al. (1959) Some observations on the treatment of post irradiation hematopoietic depression in man by the infusion of stored autogenous bone marrow. Ann Intern Med 51: 1204– 1219

    Google Scholar 

  10. McFarland W, Granville NB, Dameshek W (1959) Autologous bone marrow infusion as an adjunct in therapy of malignant disease. Blood 14: 503–521

    PubMed  CAS  Google Scholar 

  11. Appelbaum FR, Thomas ED (1983) Review of the use of marrow transplantation in the treatment of non-Hodgkin’s lymphoma. J Clin Oncol 1: 440–447

    PubMed  CAS  Google Scholar 

  12. Armitage JO, Jagannath S, Spitzer G et al. (1986) High dose therapy and autologous marrow rescue as salvage treatment for patients with large cell lymphoma. Eur J Cancer Clin Oncol 22: 871–877

    Article  PubMed  CAS  Google Scholar 

  13. Anderson KC, Nadler LM (1986) Autologous bone marrow transplantation in the therapy of lymphomas. In: De Vita VT, Hellman S, Rosenberg SA (eds), Important advances in oncology Lippincott, Philadelphia

    Google Scholar 

  14. Santos GW (1985) Overview of autologous bone marrow transplantation (ABMT). Int J Cell Cloning 3: 215–216

    Google Scholar 

  15. Frei E III (1979) Antitumor agents - dose response curve, clinical and experimental consideration. Exp Hematol (Suppl) 7: 262–264

    Google Scholar 

  16. Frei E, Canellos GP (1980) Dose, a critical factor in cancer chemotherapy, Am J Med 69: 585–594

    Article  PubMed  Google Scholar 

  17. Skipper HE, Schabel FM, Jary R, Wilcox WS (1964) Experimental evaluation of potential anticancer agents. Cancer Chemother Rep 35: 1–111

    PubMed  CAS  Google Scholar 

  18. Hill RP, Stanley JA (1975) The response of hypoxic B16 melanoma cells to in vivo treatment with chemotherapeutic agents. Cancer Res 35: 1147–1153

    PubMed  CAS  Google Scholar 

  19. Smith I, Evans B, Harland S, Millar J (1983) Autologous bone marrow rescue is unnecessary after very high-dose cyclophosphamide. Lancet 1: 76–77

    Article  PubMed  CAS  Google Scholar 

  20. Johnson DB, Leflf RS, Smith M et al. (1986) Prolongation of survival with adjuvant chemotherapy of malignant glioma with high dose BCNU (HDBCNU) and autologous bone marrow transplantation (ABMTX): an update. Proc Am Soc Clin Oncol 5: 139 (543)

    Google Scholar 

  21. Takvorian T, Parker LM, Hockberg FH et al. (1983) Autologous bone marrow transplantation: host effects of high dose BCNU. J Clin Oncol 1: 610

    PubMed  CAS  Google Scholar 

  22. Hildebrand J, Badjou R, Collard-Ronge E et al. (1980) Treatment of brain gliomas with high dose of CCNU and autologous bone marrow transplantation. Biomedicine 32: 71–75

    PubMed  CAS  Google Scholar 

  23. Lazarus H, Herzig R, Wolff S et al. (1985) Treatment of metastatic malignant melanoma with intensive melphalan and autologous bone marrow transplantation. Cancer Treat Rep 69: 473–477

    PubMed  CAS  Google Scholar 

  24. Cornbleet MA, McElwain TJ, Kumar PJ et al. (1983) Treatment of advanced malignant melanoma with High-dose melphalan and autologous bone marrow transplantation. Br J Cancer 48: 329–334

    Article  PubMed  CAS  Google Scholar 

  25. Ozols R, Corden B, Jacob J et al. (1984) High-dose cisplatin in hypertonic saline. Ann Intern Med 100: 19–24

    PubMed  CAS  Google Scholar 

  26. Howell SB, Pfeifle CE, Wung WE et al. (1982) Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 97: 845–851

    PubMed  CAS  Google Scholar 

  27. Sarna G, Champlin R, Wells J, Gale R (1982) Phase I study of high-dose mitomycin with autologous bone marrow support. Cancer Treat Rep 66: 277

    PubMed  CAS  Google Scholar 

  28. Schilcher R, Young J, Ratanatharathorn V, Karanes C, Baker L (1984) Clinical pharmacokinetics of high-dose mitomycin C, Cancer Chemother Pharmacol 13: 186–190

    Article  PubMed  CAS  Google Scholar 

  29. Brown R, Herzig R, Fay J et al. (1986) A phase I-II study of high-dose N, N1, N2- triethylenethiophosporhamide (Thio-Tepa) and autologous marrow transplantation (AMT) for refractory malignancies. Proc Am Soc Clin Oncol 5: 127 (494)

    Google Scholar 

  30. Wolff S, Fer M, McKay C et al. (1983) High dose VP16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study. J Clin Oncol 1: 701

    PubMed  CAS  Google Scholar 

  31. Leff RS, Johnson DB, Daly MB et al. (1986) High response rate with minimal toxicity in the treatment of metastatic colon carcinoma with high dose melphalan and autologous bone marrow transplantation (ABMT). Proc Am Soc Clin Oncol 5: 158 (619)

    Google Scholar 

  32. Knight W, Page CP, Kuhn JG et al. (1984) High dose L-PAM and autologous marrow infusion for refractory solid tumors. Proc Am Soc Clin Oncol 3: 150

    Google Scholar 

  33. Schabel F (1978) Patterns of resistance and therapeutic synergism among alkylating agents. Fundam Cancer Chemother 23: 200–215

    CAS  Google Scholar 

  34. Goldenberg GJ, Vanstone CL, Israels LG et al. (1970) Evidence for a transport carrier of nitrogen mustard in nitrogen mustard sensitive and resistant L51784 lymphoblasts. Cancer Res 30: 2285–2291

    PubMed  CAS  Google Scholar 

  35. Schabel FM (1983) Combination chemotherapy. In: Montgomery J (ed) Cancer chemotherapy: the biochemistry. Proceedings of a symposium at MD Anderson Hospital, Houston Decker, New York, pp 2–69

    Google Scholar 

  36. Schabel FM (1975) Synergism and antagonism among antitumor agents. In: The pharmacological basis of cancer chemotherapy. Williams and Wilkins, Baltimore, A pp 595–623, B 756

    Google Scholar 

  37. Frei E III, Cucchi C, Rosowsky A et al. (1985) Alkylating agent resistance. In vitro studies of human cell lines. Proc Natl Acad Sci USA 82: 2158–2162

    Google Scholar 

  38. Goldenberg GJ, Lam HY, Begleiter A (1979) Active carrier-mediated transport of melphalan by two separate amino acid transport systems in LPC-1 plasmacytoma cells in vitro. J Biol Chem 254: 1057–1064

    PubMed  CAS  Google Scholar 

  39. Redwood WR, Colvin M (1980) Transport of melphalan by sensitive and resistant L1210 cells. Cancer Res 40: 1144–1149

    PubMed  CAS  Google Scholar 

  40. Vistica DT, Toal J, Rabinowitz M (1978) Amino acid-conferred protection against melphalan-characterization of melphalan transport and correlation of uptake with cytotoxicity in cultured LI210 murine leukemia cells. Biochem Pharmacol 27: 2865–2870

    Article  PubMed  CAS  Google Scholar 

  41. Suzukake K, Petro BJ, Vistica DT (1982) Reduction in glutathione content of LPAM resistant LI210 cells confers drug sensitivity. Biochem Pharmacol 31: 121–124

    Article  PubMed  CAS  Google Scholar 

  42. Thomas CB, Osieka R, Kohn KW (1978) DNA cross linking by in vivo treatment with l-(2-chloroethyl)-3-(4-methylcyclohexyl)-l-nitrosourea of sensitive and resistant human colon carcinoma xenografts in nude mice. Cancer Res 38: 2448–2454

    PubMed  CAS  Google Scholar 

  43. Sedgwick B, Lindahl T (1982) A common mechanism for repair of 06 methylguanine anc: 06 ethylguanine in DNA. J Mol Biol 154: 169–175

    Article  Google Scholar 

  44. Byiield JE, Calabro-Jones P (1981) Carrier-dependent and carrier-independent transport of anticancer alkylating agents. Nature 294: 281–282

    Article  Google Scholar 

  45. Green JA, Vistica DT, Young RC et al. (1984) Melphalan (ME) resistance (R) in human ovarian cancer (OC). Potentiation of ME cytotoxicity by nutritional and pharmacologic depletion of intracellular glutathione (GSH) levels. Proc Am Assoc Cancer Res 25: 290

    Google Scholar 

  46. Brent TP (1984) Suppression of chloroethylnitrosourea-induced DNA crosslink formation by an activity isolated from human leukemic lymphoblasts. Proc Am Assoc Cancer Res 25: 288

    Google Scholar 

  47. Meyn RE, Jenkins SF, Thompson LH (1982) Defective removal of DNA cross links in a repair deficient mutant of Chinese hamster cells. Cancer Res 42: 3106–3110

    PubMed  CAS  Google Scholar 

  48. Colvin M (1982) The alkylating agents. In Chabner B (ed) Pharmacologic principles of cancer treatment. Saunders, Philadelphia, pp 276–308

    Google Scholar 

  49. Teicher B, Cucchi C, Lee J et al. (1986) Alkylating agents. In vitro studies of cross- resistance patterns. Cancer Res 46: 4379–4383

    Google Scholar 

  50. Hochberg F, Parker L, Takvorian T et al. (1981) High-dose BCNU with autologous bone marrow rescue for recurrent glioblastoma multiforme. J Neurosurg 54: 455–460

    Article  PubMed  CAS  Google Scholar 

  51. Kuwamura K, Kokunai T, Kanazawa Y, Yamada T (1982) High-dose chemotherapy with autologous bone marrow rescue for malignant brain tumors. Neurol Med Chir (Tokyo) 22: 353–359

    CAS  Google Scholar 

  52. Phillips G, Fay J, Herzig G et al. (1985) Autologous bone marrow transplantation (ABMT) in malignant glioma. Int J Cell Cloning 3: 257

    Google Scholar 

  53. Appelbaum FR, Strauchen JA, Graw RG et al. (1976) Acute lethal carditis caused by high dose combination chemotherapy, a unique clinical and pathologic indice. Lancet 1: 58–62

    Article  PubMed  CAS  Google Scholar 

  54. McElwain TJ, Hedley DW, Burton G et al. (1979) Marrow auto transplantation accelerates hematologic recovery in patients with malignant melanoma treated with high dose melphalan. Br J Cancer 40: 72–80

    Article  PubMed  CAS  Google Scholar 

  55. Skipper HE (1974) Combination therapy: some concepts and results. Cancer Chemother Rep 4: 137–145

    CAS  Google Scholar 

  56. Skipper HE (1983) Stepwise progress in the treatment of disseminated cancers. Cancer 51: 1773–1776

    Article  PubMed  CAS  Google Scholar 

  57. Skipper HE (1967) Criteria associated with destruction of leukemia and solid tumor cells in animals. Cancer Res 27: 2636–2645

    PubMed  CAS  Google Scholar 

  58. Frei E III, Freireich EJ (1965) Progress and perspectives in the chemotherapy of acute leukemia. Adv Chemother 2: 269–289

    PubMed  CAS  Google Scholar 

  59. Frei E III, Karon M, Levin RH, Freireich EJ, Taylor RJ, Hananian J et al. (1965) The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood 26: 642–656

    PubMed  Google Scholar 

  60. Freireich EJ, Henderson ES, Karon MR, Frei E III (1968) The treatment of acute leukemia with respect to cell population kinetics. In: The proliferation and spread of neoplastic cells. 21st Annual symposium on Fundamental cancer research. University Texas, MD Anderson Hospital and Tumor Institute at Houston. University of Texas Press, Houston, pp 441–452

    Google Scholar 

  61. De Vita VT, Serpik A, Carbone PP (1970) Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med 73: 881

    Google Scholar 

  62. Pinkel D (1979) Ninth annual David Karnofsky lecture: treatment of acute lymphocytic leukemia. Cancer 43: 1128– 1137

    Google Scholar 

  63. Fay J, Levine M, Phillips Gl et al. (1981) Treatment of metastatic melanoma with intensive 1, 3-bis(2-chloroethyl)-l-nitrosourea (BCNU) and autologous marrow transplantation (AMTX). Clinical trials: sarcomas and other solid tumors. Proc Am Soc Clin Oncol 22: A532

    Google Scholar 

  64. Herzig GP, Phillips GL, Herzig RH et al. (1981) High dose nitrosourea (BCNU) and autologous bone marrow transplantation: a phase I trial. In: Prestaykoaw C, Baker LH et al. (eds) Nitrosoureas, current status and new developments. Academic, New York, pp 337–341

    Google Scholar 

  65. Eder JP, Antman K, Peters W et al. (1986) High dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol 4: 1592–1597

    PubMed  CAS  Google Scholar 

  66. Teicher BA, Holden SA, Cucchi CA et al. (1988) Combination of N, AW-triethylene-thiophosporamide and cyclophosphamide in vitro and in vivo. Cancer Res 48: 94–100

    PubMed  CAS  Google Scholar 

  67. Eder JP, Antman K, Elias A, Shea TC, Teicher B, Henner WD, Schryber SM, Holden S, Finberg R, Critchlow J, Flaherty M, Mick R, Schnipper LE, Frei E III (1988) Cyclophosphamide and thiotepa with autologous bone marrow transplantation with solid tumors JNCI 80: 1221–1226

    PubMed  CAS  Google Scholar 

  68. Sledge GW, Loehrer PJ, Roth BJ, Einhorn LH (1988) Cisplatin as first line therapy for metastatic breast cancer. Indiana School of Medicine and VA Medical Center, Indianapolis J Clin Oncol 6: 1811–1814

    Google Scholar 

  69. Cocconi G, Bisagni V, De Lisi G, Ceci, Brugia M, Collozza MA, Roverselli I, Moscioni AM, Bacchi M (1988) Platinum and etoposide as a first-line chemotherapy for metastatic breast carcinoma-preliminary results of a prospective randomized trial. Proc Am Soc Clin Oncol 7: 13

    Google Scholar 

  70. Shea TC, Flaherty M, Elias A, Eder JP, Antman K, Begg C, Schnipper L, Frei E III, Henner WD (1989) A phase I study of clinical and pharmacological carboplatin. J Clin Oncol 7: 651–661

    PubMed  CAS  Google Scholar 

  71. Brooke D, Bequette RJ, RE Davis (1973) Chemical stability of cyclo-phosphamide in parenteral solutions. Am J Hosp Pharm 30: 134–137

    PubMed  CAS  Google Scholar 

  72. Cohen BE, Egorin MJ, Nayar MSB, Gutierriz P (1984) Effects of pH and temperature on the stability and decomposition of TV, N; 1 N"-triethylinethiophosphoramide in urine and buffer. Cancer Res 44: 4312–4316

    PubMed  CAS  Google Scholar 

  73. Storb R, Buckner CD, Dillingham LA, Thomas ED (1970) Cyclophosphamide regimens in rhesus monkeys with and without marrow infusions. Cancer Res 30: 2195–2203

    PubMed  CAS  Google Scholar 

  74. Bruce WR, Meeker BE, Valeriote FA (1966) Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony forming cells to chemotherapeutic agents administered in vivo. J Natl Cancer Inst 37: 233–245

    PubMed  CAS  Google Scholar 

  75. Voelcker G, Wagner T, Wientzek C, Hohorst HJ (1984) Correlation of human pharmacokinetics of “activated” cyclophosphamide and therapeutic efficacies. Cancer 54: 1179–1186

    Article  PubMed  CAS  Google Scholar 

  76. Henner WD, Peters WP, Eder JP et al. (1986) Pharmacokinetics and immediate effects of high dose carmustine in man. Cancer Treat Rep 70: 877–880

    PubMed  CAS  Google Scholar 

  77. Levin NA, Hoffman W, Weinkam RJ (1987) Pharmacokinetics of BCNU in man-a preliminary study of 20 patients. Cancer Treat Rep 62: 1305–1312

    Google Scholar 

  78. Henner WD, Shea TC, Furlog EA et al. (1987) Pharmacokinetics of continuous infusion high dose thioTEPA. Cancer Treat Rep 71: 1043–1047

    PubMed  CAS  Google Scholar 

  79. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481

    Article  Google Scholar 

  80. Mantel N (1963) Chisquare tests with one degree of freedom: extensions of the Mantel-Haenzel procedure procedure. J Am Stat Assoc 58: 690–700

    Article  Google Scholar 

  81. Mick R, Begg CB, Antman K, Korzun AH, Frei E III (1989) Diverse prognosis in metastatic breast cancer: who should be offered alternative initial therapies? Breast Cancer Res Treatm 13: 33–38

    Article  CAS  Google Scholar 

  82. Mulder NH, Meinesz AP, Sleijffer DT et al. (1984) High-dose etoposide with or without cyclophosphamide and autologous bone marrow transplantation in solid tumors. In: McKie JG, Dalesio O, Smith IE (eds) Autologous bone marrow transplantation and solid tumors. Raven, New York, pp 125–130

    Google Scholar 

  83. Wolff S, Fer M, Mckay C (1983) High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study. J Clin Oncol 1: 701–705

    PubMed  CAS  Google Scholar 

  84. Tannir N, Spitzer G, Schell F, Legha S, Zander A, Blumenschein G (1983) Phase II study of high-dose amsacrine and autologous bone marrow transplantation in patients with refractory metastatic breast cancer. Cancer Treat Rep 67: 599–600

    PubMed  CAS  Google Scholar 

  85. Ariell (1975) Treatment of disseminated cancer by intravenous hydroxyurea and autogenous bone-marrow transplants: experiences with 35 patients. J Surg Ongol 7: 331–335

    Article  Google Scholar 

  86. Knight WA, Page CP, Kuhn JG et al. (1984) High dose L-pam with autologous bone marrow infusion for advanced, steroid hormone receptor negative breast cancer (Abstract). Breast Cancer Res Treat 4: 336

    Google Scholar 

  87. Corringham R, Gilmore M, Prentice H, Boesen E (1983) High-dose melphalan with autologous bone marrow transplant: treatment of poor prognosis tumors. Cancer 52: 1783–1787

    Article  PubMed  CAS  Google Scholar 

  88. Maraninchi D, Gastuat JA, Herve P et al. (1984) High-dose melphalan and autologous marrow transplantation in adult solid tumors: clinical responses and preliminary evaluation of different strategies. In: McKie JG, Dalesio O, Smith IE (eds) Autologous bone marrow transplantation and solid tumors. Raven, New York, pp 145— 150

    Google Scholar 

  89. Lazarus J, Jerzig R, Graham-Pole J et al. (1983) Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. J Clin Oncol 2: 359–367

    Google Scholar 

  90. Tannir N, Spitzer G, Dicke K, Schell F, Distefano A, Blumenschein G (1984) Phase I-II study of high-dose mitomycin with autologous bone marrow transplantation in refractory metastatic breast cancer. Cancer Treat Rep 68: 805–806

    PubMed  CAS  Google Scholar 

  91. Schilcher RB, Young JD, Ratanathorathorn V, Baker LH (1982) High dose mitomycin C and autologous bone marrow transplantation: clinical results and pharmacokinetics. Blut 45: 183

    Google Scholar 

  92. Le Maistre CF, Herzig GP, Herzig RH et al. (1987) High dose thiotepa and autologous bone marrow rescue for the treatment of refractory breast cancer. Breast Cancer Res Treat. 10: 89

    Google Scholar 

  93. Lazarus HM, Reed MD, Spitzer TR, Rabaa MS, Blumer JL (1987) High-dose IV thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer. Cancer Treat Rep. 71: 689–695

    PubMed  CAS  Google Scholar 

  94. Slease RB, Reitz CL, Hughes WL et al. (1987) Autologous bone marrow transplantation for metastatic breast carcinoma. In: Dicke K, Spitzer TR, Jagannath S (eds) Autologous bone marrow transplantation: proceedings of the third international symposium. University of Texas MD Anderson Hospital Press, Houston, pp 489– 496

    Google Scholar 

  95. Stewart P (1982) Autologous bone marrow transplantation in metastatic breast cancer. Breast Cancer Res Treat 2: 85–92

    Article  PubMed  CAS  Google Scholar 

  96. Kessinger A, Armitage A, Landmark J, Weisenburger D (1986) Reconstitution of human hematopoietic function with autologous cryopreserved circulating stem cells. Exp Hematol 14: 192–196

    PubMed  CAS  Google Scholar 

  97. Niederwieser D, Aulitzky, Frommhold H et al. (1987) Bone marrow transplantation in the treatment of haematological malignancies and solid tumors. Wien Klin Wochenschr 99: 49–53

    PubMed  CAS  Google Scholar 

  98. Douer D, Champlin R, Ho W et al. (1981) High-dose combined-modality therapy and autologous bone marrow transplantation in resistant cancer. Am J Med 71: 973–976

    Article  PubMed  CAS  Google Scholar 

  99. Slease RB, Benear JB, Selby GB et al. (1988) High-dose combination alkylating agent therapy with autologous bone marrow rescue for refractory solid tumors. J Clin Oncol 6: 1314–1320

    PubMed  CAS  Google Scholar 

  100. Eder JP, Antman K, Elias A et al. (1987) High-dose combination alkylating agents (HDCCA) and autologous bone marrow support for metastatic breast cancer. Breast Cancer Treat 10: 89

    Google Scholar 

  101. Maraninchi D, Piana L, Blaise D et al (1987) Phase I and II studies of high-dose alkylating agents in poor-risk patients with breast cancer with autologous bone marrow transplantation. In: Dicke K, Spitzer TR, Jagganath S (eds) Autologous bone marrow transplantation: proceedings of the third international symposium. University of Texas MD Anderson Hospital Press, Houston, pp 475–480

    Google Scholar 

  102. Tajima T, Sonoda H, Kubnota M et al. (1983) High-dose combination chemotherapy with autologous bone marrow transplantation in breast carcinoma. Gan To Kagaku Ryoho 10: 840–847

    PubMed  CAS  Google Scholar 

  103. Tobias J, Weiner F, Griffiths C (1977) Cryopreserved autologous marrow infusion following high dose cancer chemotherapy. Eur J Cancer 13: 269–277

    Article  PubMed  CAS  Google Scholar 

  104. Robinson W, Hartmann D, Mangalik A et al. (1981) Autologous non frozen bone marrow transplantation after intensive chemotherapy: a pilot study. Acta Haematol 66: 145–153

    Article  PubMed  CAS  Google Scholar 

  105. Peters WP, Shpall EJ, Jones RB, Olsen GA, Bast RC, Gockerman JP, Moore JO (1988) High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 6: 1368–1376

    PubMed  CAS  Google Scholar 

  106. Gisselbrecht C, Lepage E, Espei M et al. (1987) Cyclophosphamide, total body irradiation with autologous bone marrow support for metastatic breast cancer. Proc Am Soc Clin Oncol 6: 65

    Google Scholar 

  107. Livingston R, Schulman S, Griffin B et al. (1987) Combination chemotherapy and systemic irradiation consolidation for poor prognosis breast cancer. Cancer 9: 1249–1254

    Article  Google Scholar 

  108. Spitzer G, Buzdar A, Auber M et al. (1987) High dose cyclophosphamide/VP- 16/platinum intensification for metastatic breast cancer. Breast Cancer Res Treat 10: 89

    Google Scholar 

  109. Jones RB, Shpall EJ, Peters WP (1987) AFM-intensive induction chemotherapy for advanced breast cancer (Abstract). Breast Cancer Res Treat 10: 90

    Google Scholar 

  110. Bitran JD, Williams SF (1987) A phase II study of induction chemotherapy followed by intensification with high dose chemotherapy with autologous bone marrow rescue (ABMR) in stage IV breast cancer (Abstract). Breast Cancer Res Treat 10: 88

    Google Scholar 

  111. Leoni M, Rosti GF, Flamini et al. (1988) High-dose chemotherapy and ABMT in advanced breast cancer: a pilot study. Bone Marrow Transplant 3: 299

    Google Scholar 

  112. Ingle JN, Tormey DC, Tan KH (1978) The bone marrow examination in breast cancer: diagnostic considerations and clinical usefulness. Cancer 41: 670–674

    Article  PubMed  CAS  Google Scholar 

  113. Kufe D, Inghirami G, Hayes AM, Wheeler J, Schlom J (1984) Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 3: 223–232

    Article  PubMed  CAS  Google Scholar 

  114. Hilkens J, Buijs F, Hilgers J et al. (1983) Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer 34: 197–206

    Article  Google Scholar 

  115. Redding WH, Monaghan P, Imrie SF et al. (1983) Detection of micrometastases in patients with primary breast cancer. Lancet 2: 1271–1274

    Article  PubMed  CAS  Google Scholar 

  116. Mann SL, Joshi SS, Weisenburger DD et al. (1986) Detection of tumor cells in histologically normal bone marrow of autologous transplant patients using culture techniques. Exp Hematol 14: 541

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. DFCI, 44 Binney Street, Boston, MA, 02115, USA

    K. H. Antman, J. P. Eder, A. Elias, T. C. Shea, B. Teicher, W. D. Henner, S. Schryber, J. Critchlow, C. Begg, L. E. Schnipper & E. Frei III

Authors
  1. K. H. Antman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. P. Eder
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Elias
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. C. Shea
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. Teicher
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. W. D. Henner
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. Schryber
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. Critchlow
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C. Begg
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. L. E. Schnipper
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. E. Frei III
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medical Oncology, British Columbia Cancer Agency, 600 West 10th Avenue, V5Z 4E6, Vancouver, B.C., Canada

    Joseph Ragaz MD, FRCP

  2. Foundation for Clinical Research Inc., 80 East End Avenue, 10028, New York, NY, USA

    Irving M. Ariel MD

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer-Verlag Berlin · Heidelberg

About this chapter

Cite this chapter

Antman, K.H. et al. (1991). High-Dose Chemotherapy in Breast Cancer. In: Ragaz, J., Ariel, I.M. (eds) High-Risk Breast Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-74728-1_25

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-74728-1_25

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-74730-4

  • Online ISBN: 978-3-642-74728-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation